Bio-Rad Laboratories Class B (BIO.B)

Bio-Rad Laboratories Class B is the common stock of Bio-Rad Laboratories, Inc., a healthcare company focused on life science research and clinical diagnostics. The company develops, manufactures, and distributes products used in research, biopharmaceutical production, quality control, food safety, science education, and clinical testing. Its operations are organized into two segments: Life Science, which provides instruments, systems, reagents, and consumables for separating, purifying, characterizing, and measuring biological materials, and Clinical Diagnostics, which supplies diagnostic test systems, informatics tools, test kits, quality controls, and related software for laboratory and physician office settings. Bio-Rad serves customers across the United States and internationally through direct sales and distribution partners. Founded in 1952, the company is headquartered in Hercules, California.


Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NYSE-BIO.B
$410.22
8.7% Upside
Fair
Not available
Not available
Good
0.0%
February 18, 2027
9.8x
1.3x
3.9x
10.062 B
3.489 B
12.3%
80.0%
3.6
32.2%
Valuation • Fair Value

Bio-Rad Laboratories Class B (NYSE-BIO.B) Fair Value by Valuation Model

Review the available estimates for Bio-Rad Laboratories Class B (NYSE-BIO.B), including DCF Fair Value, Ben Graham Formula Value, EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$410.22

Estimated upside of 8.7% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$445.44

Discounted cash flow valuation reference.

Ben Graham Formula Value

$422.03

Classic Ben Graham valuation formula reference.

EPV Fair Value

$430.73

Earnings power value estimate.

Comps Fair Value

$371.57

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 6 available valuation references for Bio-Rad Laboratories Class B (NYSE-BIO.B) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Bio-Rad Laboratories Class B (NYSE-BIO.B)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

2.593 B

Current operating scale indicator.

Revenue Forecast

2.586 B

Forward revenue estimate.

EBITDA

410.9 M

Current operating profitability reference.

EBITDA Forecast

401.9 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Bio-Rad Laboratories Class B (NYSE-BIO.B) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Bio-Rad Laboratories Class B (NYSE-BIO.B)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Good

Positive financial-health read.

Piotroski Score

5

Mid-range quality score.

Beneish M-Score

-2.34

No elevated caution signal from this screen.

Altman Z-Score

3.6

Relatively strong balance-sheet zone.

FCF / Net Income

32.2%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Bio-Rad Laboratories Class B (NYSE-BIO.B). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Bio-Rad Laboratories Class B (NYSE-BIO.B)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

February 18, 2027

Days to Earnings

97

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Bio-Rad Laboratories Class B (NYSE-BIO.B), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Buy

The 15-minute technical read for Bio-Rad Laboratories Class B (NYSE-BIO.B) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Buy

The 1-hour technical read for Bio-Rad Laboratories Class B (NYSE-BIO.B) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Bio-Rad Laboratories Class B (NYSE-BIO.B) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Bio-Rad Laboratories Class B (NYSE-BIO.B) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Bio-Rad Laboratories Class B (NYSE-BIO.B) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Bio-Rad Laboratories Class B (NYSE-BIO.B) Stock FAQ

Data-supported answers about Bio-Rad Laboratories Class B (NYSE-BIO.B), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$410.22
Estimated upside 8.7%
Valuation Rating
Undervalued
Estimated upside of 8.7%
Financial Health
Good
Current financial-health read

The current fair value estimate for Bio-Rad Laboratories Class B (NYSE-BIO.B) is $410.22. This implies an estimated upside of 8.7% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 8.7% versus the current market price.

The current financial health read for Bio-Rad Laboratories Class B (NYSE-BIO.B) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Bio-Rad Laboratories Class B (NYSE-BIO.B) is February 18, 2027.

The latest available data indicates no current dividend yield for Bio-Rad Laboratories Class B (NYSE-BIO.B).

The current P/E ratio listed for Bio-Rad Laboratories Class B (NYSE-BIO.B) is 9.8x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Bio-Rad Laboratories Class B is 10.062 B.

The current enterprise value listed for Bio-Rad Laboratories Class B is 3.489 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Bio-Rad Laboratories Class B is NYSE-BIO.B, and the stock is listed on NYSE.

Bio-Rad Laboratories Class B (NYSE-BIO.B) is listed on NYSE.

The current debt-to-total-capital ratio listed for Bio-Rad Laboratories Class B is 12.3%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Bio-Rad Laboratories Class B is 80.0%. Free float helps investors understand how much of the share base is available for public trading.